Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected

BACHEM HOLDING AG

20/12/2024 10:47

LONDON/COPENHAGEN, Dec 20(Reuters) - Novo Nordisk
 NOVOb.CO  said on Friday its experimental next-generation
obesity drug CagriSema helped overweight patients cut their
weight by 22.7% in a late-stage trial, below the 25% it had
expected.
    The lower-than-expected weight loss from the drug candidate
deals a blow to the Danish drugmaker's ambitions for a successor
to its popular Wegovy more powerful than Eli Lilly's Zepbound.
    Investors and analysts had eagerly awaited this data as a
test of Novo's case that it has a strong pipeline of drugs to
follow Wegovy in the fiercely competitive anti-obesity market. 


 (Reporting by Maggie Fick in London and Stine Jacobsen and
Louise Rasmussen in Copenhagen, Ludwig Burger in Frankfurt;
Editing by Josephine Mason and Catherine Evans)